NEW YORK, Nov. 10 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on The Medical House PLC (LSE: MLH.L), based in Sheffield, United Kingdom. The full 48-page report can be found at http://www.crystalra.com.
The Medical House PLC ("TMH" or "the Company") designs drug delivery platforms for the pharmaceutical and biotechnology industries. Employing the right delivery device can be critical for determining treatment adherence and efficacy. The Company's primary product line is a family of devices known as the AutoSafety Injector (ASI(TM)) autoinjector platform that is intended to offer patients an easier, safer, and more convenient self-injection method. The ASI(TM) autoinjector is entirely automated-from needle insertion and medication injection to needle withdrawal and full retraction back into the device. When the shot is completed, the entire unit is disposable. With an ASI(TM) autoinjector device, patients never see or handle a needle, thereby reducing the anxiety that many people have about self-injections and eliminating the risk of accidental needlestick injuries. The ASI(TM) autoinjector technology also removes guesswork about dosing. Its prefilled syringes and automated delivery process ensure that patients receive accurate and consistent doses -- a feature designed to improve treatment compliance and efficacy as well as reduce users' dependence on their clinicians. The Company has also developed a second delivery platform, reusable needle-free jet injectors. TMH has received Europe's CE Mark and the U.S. Food and Drug Administration's (FDA) 510(k) clearance for versions of the ASI(TM) autoinjector family and the reusable needle-free jet injectors.
In addition, several entities have licensed TMH's platforms as a means to deliver proprietary medications. TMH has partnerships for its ASI(TM) autoinjector platform with Dr. Reddy's Laboratories Ltd. (RDY-NYSE), Catalent Pharma Solutions, Inc. and Stallergenes SA (GENP-EPA), a European government agency, and an undisclosed global pharmaceutical partner that licensed an ASI(TM) autoinjector system in an agreement valued at up to 34 million pounds Sterling over its first six years. Further, TMH anticipates the future launch of its needle-free jet injector technology for injection of human Growth Hormone (hGH) in collaboration with Merck Serono International S.A.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of thirty-eight thousand, five hundred dollars and one hundred thousand Warrants/Options for its services in creating this report, for updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the London Stock Exchange.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
|SOURCE Crystal Research Associates, LLC|
Copyright©2008 PR Newswire.
All rights reserved